Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sabestomig - Astrazeneca

Next Previous
X
Search
Drug Profile

Sabestomig - Astrazeneca

Alternative Names: AZD-7789

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma
  • Phase I/II Hodgkin's disease; Solid tumours

Most Recent Events

  • 16 Apr 2024 Presage Biosciences and AstraZeneca plans a phase 0 trial for Squamous cell carcinoma (Metastatic disease, Recurrent) in USA (Intratumoural, Injection) in April 2024 (NCT06366451)
  • 09 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Hodgkin's disease presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 30 Nov 2023 AstraZeneca in-licenses CIVO® technology from Presage Biosciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top